Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News How Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia patients Find out how Syndax’s Revuforj (revumenib) became the first FDA-approved menin inhibitor for acute leukemia, transforming treatment and investor sentiment alike. bySoujanya RaviOctober 24, 2025